Trastuzumab envedotin

重组人源化抗HER2单抗-MMAE偶联药物（石药集团中奇制药）

Report date: 2025/05/23 14:39:10

Base Information

Drug NameTrastuzumab envedotin
Drug Alias NameDP-303cDP303cSYSA1501SYSA-1501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsTubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences +[4] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A